Abstract:IMPORTANCE: Cell therapy has been a potential approach for ST-segment elevation acute myocardial infarction (STEMI). To improve the therapeutic oucome, the safety and efficacy of hypoxia-preconditioned (H-) bone marrow mononuclear cells (BMCs) in AMI patients need further evaluation. OBJECTIVE: To investigate the safety and efficacy of H-BMCs therapy in AMI patients. DESIGN: A phase 1, randomized and blinded study (February, 2011~ March, 2012) with one-year of follow-up. SETTING: A single center for hospitalized care. PARTICIPANTS: 22 Patients with an acute ST elevation myocardial infarction were recruited and randomized to two groups: normoxia BMCs (N-, n=11) and H-BMCs (n=11). INTERVENTIONS: Intracoronary infusion of H-BMCs or N-BMCs within 5-7 days after treatment with percutaneous transluminal coronary intervention (PCI). Patients were similarly treated by a stop-flow technique through an over-the-wire balloon catheter. MAIN OUTCOMES AND MEASURES: Primary endpoint was Treatment-emergent 30-day serious adverse event rate defined as a composite of death, MI, sustained ventricular tachycardia, stroke, hospitalization for worsening heart failure and revascularization. Secondary endpoints were change of myocardium perfusion, global left ventricular ejection fraction and left ventricular volumes. RESULTS: The primary endpoint events was none for N-BMCs and 9.1% (95% CI, 0.2%-41.3%) for H-BMCs. There was significant increase in the change of LVEF of H-BMCs group at 6 month. The change of end diastolic volume (EDV) and end systolic volume (ESV) in H-BMCs at 12 month were significantly decreased. Ratio of myocardium perfusion defect by Single-Photon Emission Computed Tomography (SPECT) was significantly reduced in H-BMCs group at 6 months, and score of myocardium perfusion defect by SPECT was significantly reduced than that of baseline in H-BMCs group at 6 and 12 months, unlike N- group. CONCLUSIONS AND RELEVANCE: Intracoronary infusion with H-BMCs appeared to be safe and effective for patients with AMI. Although the sample size precludes a definitive statement about safety and efficacy, these results provide the basis for larger studies to provide definitive evidence about safety and to assess efficacy of this new therapeutic approach.

Hypoxia tolerance of bone marrow mesenchymal stem cells

Hypoxia Inhibits the Spontaneous Calcification of Bone Marrow‐derived Mesenchymal Stem Cells

Transplantation of Hypoxia Preconditioned Bone Marrow Mesenchymal Stem Cells Enhances Angiogenesis and Neurogenesis after Cerebral Ischemia in Rats.

Transplantation of Hypoxia-Preconditioned Mesenchymal Stem Cells Improves Infarcted Heart Function Via Enhanced Survival of Implanted Cells and Angiogenesis

Erythropoietin signal pathway is upregulated in mesenchymal stem cell during hypoxia

Apoptosis of Bone Marrow Mesenchymal Stem Cells Caused by Hypoxia/reoxygenation Via Multiple Pathways.

Optimal Temporal Delivery of Bone Marrow Mesenchymal Stem Cells in Rats with Myocardial Infarction.

Effects of hypoxia preconditioning on the proliferation, apoptosis and necrosis of bone marrow derived mesenchymal stem cells (BMSCs)

Differentiation of Bone Marrow Mesenchymal Stem Cells Induced by Myo-Cardial Medium under Hypoxic Conditions

The Protective Effect of Bone Marrow Mesenchymal Stem Cells by Anoxic Preconditioning on Diabetic Cardiomyopathy

Abstract 21125: Long-Term Outcome of Administration of Hypoxia-Preconditioned Mesenchymal Stem Cells after Acute Myocardial Infarction in Nonhuman Primate Angiogenesis Persist for at Least 17 Months

Abstract 248: Comparison Of Transplantation Of Bone Marrow-derived Stem Cells, Adipose-derived Stem Cells And Endometrium- Derived Stem Cells In The Infarcted Heart

Hypoxia contributes to directed differentiation of mice bone marrow derived mesenchymal stem cells

Safety and Efficacy of Intracoronary Hypoxia-Preconditioned Bone Marrow Mononuclear Cell Administration for Acute Myocardial Infarction Patients: the China-Ami Randomized Controlled Trial

Protective Paracrine Effect of Mesenchymal Stem Cells on Cardiomyocytes

Abstract 15053: Hypoxic Preconditioning Improves the Effectiveness of Bone Marrow Mesenchymal Stem Cells for Cardiac Repair in Cynomolgus Monkeys With Myocardial Infarction

[Anti-Apoptotic Effects of Mesenchymal Stem Cells on Cardiac Myocytes: in Vitro Study with Rats].

Abstract 20556: Safety and Efficacy of Intracoronary Hypoxia-PrecondItioned Bone Marrow Mononuclear Cells Administration for Acute Myocardial Infarction Patients

Modulating autophagy in mesenchymal stem cells effectively protects against hypoxia- or ischemia-induced injury

In vitro hypoxic preconditioning of embryonic stem cells as a strategy of promoting cell survival and functional benefits after transplantation into the ischemic rat brain.

Improved Anti-Apoptotic and Anti-Remodeling Potency of Bone Marrow Mesenchymal Stem Cells by Anoxic Pre-Conditioning in Diabetic Cardiomyopathy.